Showing results (101-110 of 190) with videos related to
Sort By:
Pageof 19
Nature Communications|July 3, 2026
Spatial transcriptomic atlas of aggressive osteosarcomas reveals shared immune landscape and targetable surface markersGaël Moquin-Beaudry, Maria Eugénia Marques Da Costa, Pierre Khneisser, et al.European Journal of Cancer (Oxford, England : 1990)|December 20, 2020
Unmet needs for relapsed or refractory Wilms tumour: Mapping the molecular features, exploring organoids and designing early phase trials - A collaborative SIOP-RTSG, COG and ITCC session at the first SIOPE meetingJesper Brok, Annelies M C Mavinkurve-Groothuis, Jarno Drost, et al.Cancer Research|March 5, 2004
Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 bindingSydney M Evans, Kevin D Judy, Isolde Dunphy, et al.European Journal of Cancer (Oxford, England : 1990)|April 14, 2009
Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European ConsortiumBirgit Geoerger, Bruce Morland, Anna Ndiaye, et al.European Journal of Cancer (Oxford, England : 1990)|May 29, 2012
Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma--a report from the Société Française des Cancers et leucémies de l'Enfant et de l'adolescent (SFCE)Véronique Minard-Colin, Jean-Laurent Ichante, Laurent Nguyen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 22, 2023
Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer StudyMichela Casanova, Francisco Bautista, Quentin Campbell-Hewson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2019
Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa StudyDarren R Hargrave, Eric Bouffet, Uri Tabori, et al.European Journal of Cancer (Oxford, England : 1990)|September 20, 2021
First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trialRaphael J Morscher, Caroline Brard, Pablo Berlanga, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2024
Evolution of the Innovative Therapies for Children With Cancer Consortium Trial Portfolio for Drug Development for Children With CancerFrancisco Bautista, Jaime Verdú-Amorós, Birgit Geoerger, et al.NPJ Precision Oncology|September 20, 2023
Sequential genomic analysis using a multisample/multiplatform approach to better define rhabdomyosarcoma progression and relapseHenry de Traux de Wardin, Josephine K Dermawan, Marie-Sophie Merlin, et al.Pageof 19